In this review, we first focus on major differences of the PAM axis between normal cells and cancer cells, and then, describe current PI3K, AKT, mTORC1/mTORC2, and PDK1 inhibitors, by summarising active and completed trials in a wide range of cancers. Here, PDK1 is linked to cancer.